Latest Health News

Beonic Ltd (ASX:BEO) has initiated a $3 million pro-rata renounceable entitlement offer at $0.08 per share, partially underwritten by Alpine Capital, to shore up working capital and repay shareholder loans. The offer carries potential dilution of 35.7% for non-participating shareholders and may increase the Thorney Group's voting power significantly.

Tetratherix Limited secures $15 million via institutional placement plus a capped $2 million share purchase plan at a 14% discount, aiming to fast-track manufacturing expansion and commercial partnerships.

Acrux has amended its licensing agreement with Gedeon Richter to bring its Estradiol spray Lenzetto® to Australia, unlocking up to AUD 5.4 million in milestone payments and addressing a critical shortage in Menopause Hormone Therapy products.

HealthCo Healthcare & Wellness REIT has reached a government-backed agreement with Bethesda Health Care to operate the Mount Private Hospital, marking a significant step in resolving Healthscope-related uncertainties and ensuring long-term portfolio stability.

Thrive Tribe Technologies (ASX:1TT) is fast-tracking the relaunch of its legacy HR platforms, WooBoard and REFFIND, integrating AI features to serve enterprise, government, and defense sectors managing dispersed workforces.

International Graphite Limited and Italian chemical producer Alkeemia have formalised a joint venture to develop a major graphite processing facility in Porto Marghera, Italy, targeting 15,000 tonnes per year by 2029 with first production expected in 2027.

Recce Pharmaceuticals has signed a non-binding term sheet with a major Middle Eastern pharma player for exclusive rights to commercialise its R327 Topical Gel across the MENA region, targeting a high diabetes burden market.

Biome Australia has launched a multi-centre clinical trial for its proprietary probiotic BMB18, adding a prestigious Greek university to its research network and commencing recruitment within the expected timeline.

Savor Limited has swung back to profitability in FY26, delivering a net profit after tax of $1.3 million alongside its strongest operating margin ever at 14.5%. The hospitality group also reduced leverage significantly and is set to pay its first dividend, marking a milestone after years of losses.

Nexalis Therapeutics (ASX: NX1) has voluntarily suspended trading of its shares pending a material announcement on its existing debt funding facility, extending a recent trading halt. The suspension is set to last until the earlier of the announcement release or resumption of trading on 28 May 2026.

Bio-Gene Technology has raised A$3.21 million to complete critical safety studies for its novel insecticide Flavocide and ramp up production of its natural insecticide Qcide, advancing its path to commercialisation in multiple global markets.

Fredon, the electrical and mechanical arm of NRW Holdings (ASX:NWH), has secured $120 million in new contracts across Victoria and Western Australia, reinforcing its role in critical infrastructure projects.